Your browser doesn't support javascript.
Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.
Xiao, Yinan; Xu, Hanyue; Guo, Wen; Zhao, Yunuo; Luo, Yuling; Wang, Ming; He, Zhiyao; Ding, Zhenyu; Liu, Jiyan; Deng, Lei; Sha, Fushen; Ma, Xuelei.
  • Xiao Y; Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041 China.
  • Xu H; West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 610041 China.
  • Guo W; West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 610041 China.
  • Zhao Y; West China Hospital, Sichuan University, Chengdu, 610041 China.
  • Luo Y; West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 610041 China.
  • Wang M; West China Hospital, Sichuan University, Chengdu, 610041 China.
  • He Z; Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041 China.
  • Ding Z; West China Hospital, Sichuan University, Chengdu, 610041 China.
  • Liu J; Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041 China.
  • Deng L; West China Hospital, Sichuan University, Chengdu, 610041 China.
  • Sha F; Infectious Diseases Center, West China Hospital, Sichuan University, Chengdu, 610041 China.
  • Ma X; Department of Pharmacy, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy, Chengdu, 610041 China.
Mol Biomed ; 1(1): 16, 2020.
Article in English | MEDLINE | ID: covidwho-1515459
ABSTRACT
The outbreak of coronavirus disease 2019 (COVID-19) triggered by the new member of the coronaviridae family, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has created an unprecedented challenge for global health. In addition to mild to moderate clinical manifestations such as fever, cough, and fatigue, severe cases often developed lethal complications including acute respiratory distress syndrome (ARDS) and acute lung injury. Given the alarming rate of infection and increasing trend of mortality, the development of underlying therapeutic and preventive treatment, as well as the verification of its effectiveness, are the top priorities. Current research mainly referred to and evaluated the application of the empirical treatment based on two precedents, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), including antiviral drugs targeting different stages of virus replication, immunotherapy modulating the overactivated inflammation response, and other therapies such as herbal medicine and mesenchymal stem cells. Besides, the ongoing development of inventing prophylactic interventions such as various vaccines by companies and institutions worldwide is crucial to decline morbidity and mortality. This review mainly focused on promising candidates for the treatment of COVID-19 and collected recently updated evidence relevant to its feasibility in clinical practice in the near future.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Traditional medicine / Vaccines Language: English Journal: Mol Biomed Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Traditional medicine / Vaccines Language: English Journal: Mol Biomed Year: 2020 Document Type: Article